165 related articles for article (PubMed ID: 34088773)
1. Kidney Doses in
Mix M; Renaud T; Kind F; Nemer U; Yousetzadeh-Nowsha E; Moalosi TCG; Ormrane AM; Meyer PT; Ruf J
J Nucl Med; 2022 Feb; 63(2):253-258. PubMed ID: 34088773
[TBL] [Abstract][Full Text] [Related]
2. Examining Absorbed Doses of Indigenously Developed
Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
[No Abstract] [Full Text] [Related]
3. Renal and Multiorgan Safety of
Herrmann K; Rahbar K; Eiber M; Sparks R; Baca N; Krause BJ; Lassmann M; Jentzen W; Tang J; Chicco D; Klein P; Blumenstein L; Basque JR; Kurth J
J Nucl Med; 2024 Jan; 65(1):71-78. PubMed ID: 38050121
[TBL] [Abstract][Full Text] [Related]
4. Radiation Dosimetry for
Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
6. Prediction of Response to
Hohberg M; Reifegerst M; Drzezga A; Wild M; Schmidt M
J Nucl Med; 2023 Nov; 64(11):1758-1764. PubMed ID: 37652546
[TBL] [Abstract][Full Text] [Related]
7. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
8. An Intrapatient Dosimetry Comparison of
Rinscheid A; Gäble A; Wienand G; Pfob C; Dierks A; Kircher M; Trepel M; Weckermann D; Lapa C; Bundschuh RA
J Nucl Med; 2023 Dec; 64(12):1918-1924. PubMed ID: 37770108
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Membrane Antigen Radioligand Therapy Using
Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
[TBL] [Abstract][Full Text] [Related]
10. Pretherapeutic Comparative Dosimetry of
Feuerecker B; Chantadisai M; Allmann A; Tauber R; Allmann J; Steinhelfer L; Rauscher I; Wurzer A; Wester HJ; Weber WA; d'Alessandria C; Eiber M
J Nucl Med; 2022 Jun; 63(6):833-839. PubMed ID: 34531260
[TBL] [Abstract][Full Text] [Related]
11. Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer.
Götz TI; Lang EW; Prante O; Cordes M; Kuwert T; Ritt P; Ludwig B; Schmidkonz C
Nuklearmedizin; 2020 Sep; 59(5):365-374. PubMed ID: 32663888
[TBL] [Abstract][Full Text] [Related]
12. Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with
Xue S; Gafita A; Dong C; Zhao Y; Tetteh G; Menze BH; Ziegler S; Weber W; Afshar-Oromieh A; Rominger A; Eiber M; Shi K
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4064-4072. PubMed ID: 35771265
[TBL] [Abstract][Full Text] [Related]
13. Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study.
Kaur K; Nagi S; Satapathy S; Aggarwal P; Sood A; Mittal BR
Nucl Med Commun; 2024 Feb; 45(2):115-120. PubMed ID: 37982573
[TBL] [Abstract][Full Text] [Related]
14. Kidney absorbed radiation doses for [ 177 Lu]Lu-PSMA-617 and [ 177 Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry.
Uijen MJM; Privé BM; van Herpen CML; Westdorp H; van Gemert WA; de Bakker M; Gotthardt M; Konijnenberg MW; Peters SMB; Nagarajah J
Nucl Med Commun; 2023 Apr; 44(4):270-275. PubMed ID: 36597884
[TBL] [Abstract][Full Text] [Related]
15. Intermittent Radioligand Therapy with
Mader N; Schoeler C; Pezeshkpour N; Klimek K; Groener D; Happel C; Tselis N; Mandel P; Grünwald F; Sabet A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760574
[No Abstract] [Full Text] [Related]
16. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
Widjaja L; Derlin T; Ross TL; Bengel FM; Werner RA
Prostate; 2022 Jan; 82(1):86-96. PubMed ID: 34633090
[TBL] [Abstract][Full Text] [Related]
17. Intra-therapeutic dosimetry of [
Peters SMB; Privé BM; de Bakker M; de Lange F; Jentzen W; Eek A; Muselaers CHJ; Mehra N; Witjes JA; Gotthardt M; Nagarajah J; Konijnenberg MW
Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):460-469. PubMed ID: 34218300
[TBL] [Abstract][Full Text] [Related]
18. The
Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
[TBL] [Abstract][Full Text] [Related]
19. First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [
Kurth J; Krause BJ; Schwarzenböck SM; Bergner C; Hakenberg OW; Heuschkel M
Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):123-135. PubMed ID: 31482426
[TBL] [Abstract][Full Text] [Related]
20. Dosimetry Estimate and Initial Clinical Experience with
Rathke H; Flechsig P; Mier W; Bronzel M; Mavriopoulou E; Hohenfellner M; Giesel FL; Haberkorn U; Kratochwil C
J Nucl Med; 2019 Jun; 60(6):806-811. PubMed ID: 30389816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
